<DOC>
	<DOCNO>NCT00723099</DOCNO>
	<brief_summary>This phase II trial study well umbilical cord blood transplant donor work treat patient hematological cancer . Giving chemotherapy total-body irradiation ( TBI ) donor umbilical cord blood transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell unrelated donor , exactly match patient 's blood , infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell ( call graft-versus-host disease ) . Giving cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Donor Umbilical Cord Blood Transplant Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Estimate probability one year survival . II . For Arm 2 : Demonstrate equivalent improve engraftment rate non-anti-thymocyte globulin ( ATG ) base condition regimen . Patients consider graft failure/rejections provide meet criterion list : - Absence 3 consecutive day neutrophils &gt; = 500/ul combine host cluster differentiation ( CD ) 3 peripheral blood chimerism &gt; = 50 % day 42 - Absence 3 consecutive day neutrophils &gt; = 500/ul circumstance day 55 - Death day 28 neutrophil count &lt; 100/ul without evidence engraftment ( &lt; 5 % donor CD3 ) - Primary autologous count recovery &lt; 5 % donor CD3 peripheral blood chimerism count recovery without relapse SECONDARY OBJECTIVES : I . Six month non-relapse mortality . II . Overall incidence graft failure/rejection . Patients consider graft failure/rejections provide meet criterion list : - Absence 3 consecutive day neutrophils &gt; = 500/ul combine host CD3 peripheral blood chimerism &gt; = 50 % day 42 - Absence 3 consecutive day neutrophils &gt; = 500/ul circumstance day 55 - Death day 28 neutrophil count &lt; 100/ul without evidence engraftment ( &lt; 5 % donor CD3 ) - Primary autologous count recovery &lt; 5 % donor CD3 peripheral blood chimerism count recovery without relapse III . Kinetics chimeric reconstitution . IV . Incidence neutrophil engraftment day 42 . V. Incidence platelet engraftment six month . VI . Incidence grade II-IV III-IV acute graft-versus-host disease ( GvHD ) arm day 100 . VII . Incidence one year chronic GvHD arm . VIII . Incidence clinically significant infection 6 month , 1 year , 2 year arm . IX . Probability one two year survival . X . Incidence one two year relapse disease progression . XI . Fred Hutchinson Cancer Research Center ( FHCRC ) patient : Kinetics immune reconstitution , functional quantitative assay . XII . FHCRC patient : Examination possible immunologic factor lead emergence dominant unit . OUTLINE : Patients assign 1 2 treatment arm . ARM I : CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) 1 hour day -6 -2 cyclophosphamide IV 1-2 hour day -6 . Patients undergo low dose total-body irradiation ( TBI ) day -1 . UMBILICAL CORD BLOOD TRANSPLANT : Patients undergo donor umbilical cord blood infusion day 0 . IMMUNOSUPRESSIVE THERAPIES : Patients receive cyclosporine IV 1 hour every 8-12 hour day -3 +180 mycophenolate mofetil IV orally ( PO ) every 8 hour day 0 +96 . ARM II : CONDITIONING REGIMEN : Patients receive fludarabine phosphate cyclophosphamide Arm I . Patients undergo high dose TBI day -1 . UMBILICAL CORD BLOOD TRANSPLANT : Patients undergo donor umbilical cord blood infusion Arm I. IMMUNOSUPRESSIVE THERAPIES : Patients receive cyclosporine mycophenolate mofetil Arm I . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients &gt; 70 may consider performance status &gt; 80 % Eastern Cooperative Oncology Group ( ECOG ) &lt; 1 comorbidity score &lt; 3 Adequate cardiac function define absence decompensated congestive heart failure , uncontrolled arrhythmia : Left ventricular ejection fraction &gt; = 35 % Fractional shortening &gt; 22 % Adequate pulmonary function define diffusion capacity carbon monoxide ( DLCO ) &gt; 30 % predict , absence oxygen ( O2 ) requirement Adequate hepatic function ; patient clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , histology , degree portal hypertension ; patient fulminant liver failure , cirrhosis evidence portal hypertension bridge fibrosis , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , correctable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease exclude Adequate renal function define creatinine = &lt; 2.0 mg/dl ( adult ) creatinine clearance &gt; 40 ml/min ( pediatrics ) All adult creatinine &gt; 1.2 history renal dysfunction must estimate creatinine clearance &gt; 40 ml/min Performance status score : Karnofsky ( adult ) &gt; = 60 ECOG 02 ; Lansky ( child ) score &gt; = 50 If recent mold infection , e.g. , Aspergillus , must clear infectious disease Second hematopoietic cell transplant : Must &gt; = 3 month prior myeloablative transplant Acute myeloid leukemia acute lymphoblastic leukemia , include biphenotypic acute leukemia mixedlineage leukemia : Must &lt; 5 % morphologic marrow blast evaluable marrow ( &gt; 25 % normal cellularity age ) collect less one month prior start conditioning ; patient persistently aplastic great one month since complete last chemotherapy also eligible approval principal investigator ( PI ) designee Chronic myelogenous leukemia : All type , except refractory blast crisis ; chronic phase patient must fail intolerant Gleevec tyrosine kinase inhibitor ; time transplant , patient must &lt; 5 % blast evaluable marrow ( &gt; 25 % normal cellularity age ) morphology within bone marrow Myelodysplastic syndrome ( MDS ) : Any subtype ; morphologic blast must less 5 % evaluable marrow ( &gt; 25 % normal cellularity age ) ; blast 5 % , patient require induction chemotherapy pretransplant reduce blast count le 5 % ; patient hypocellular marrow absence excess blast relate underlying disease result treatment MDS may also eligible approval PI designee Largecell lymphoma aggressive Tcell lymphoma : With chemotherapy sensitive disease fail autologous transplant patient ineligible autologous transplant ; chemotherapy sensitive disease define &gt; = 50 % reduction size tumor chemotherapy regimen immediately precede transplant Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) : Must refractory fludarabine ( fludarabine phosphate ) fail complete partial response therapy regimen contain fludarabine ( another nucleoside analog , e.g . cladribine [ 2CDA ] , pentostatin ) experience disease relapse within 12 month complete therapy regimen contain fludarabine ( another nucleoside analog ) Hodgkin disease : Must receive failed frontline therapy Follicular lymphoma , marginal zone Bcell lymphoma , lymphoplasmacytic lymphoma , mantlecell lymphoma , indolent Tcell lymphoma : Must progress recent remission duration &lt; 6 month Follicular lymphoma , marginal zone BCell lymphoma , lymphoplasmacytic lymphoma , mantlecell lymphoma , indolent Tcell lymphoma : Patients bulky disease consider debulking chemotherapy transplant ; patient refractory disease eligible , unless bulky disease estimate tumor double time le one month Multiple myeloma : Must receive prior chemotherapy ; consolidation chemotherapy autografting prior nonmyeloablative hematopoietic cell transplant ( HCT ) permit Myeloproliferative syndrome DONOR : Cord blood ( CB ) donor selection base institutional guideline general select optimize human leukocyte antigen ( HLA ) match cell dose ; additionally , CB graft shall consist one two CB donor base , exclusively determine , cell dose ( total nucleate cell [ TNC ] /kg CD34/kg ) , HLA match disease status indication transplant ; attend preference allow single versus double unit well degree mismatch base patient specific factor , long follow minimum criterion meet : HLA match Minimum requirement : The CB graft ( ) must match minimum 4/6 HLAA , B , DRB1 locus recipient . Therefore 02 mismatch A B DRB1 locus base intermediate resolution A , B antigen DRB1 allele type determination HLAmatch allow HLAmatching determine highresolution typing allow per institutional guideline long minimum criterion meet Selection two CB unit mandatory single cord blood unit meet follow criterion : Match grade 6/6 ; TNC Dose &gt; = 2.5 x 10^7/kg Match grade 5/6 4/6 ; TNC dose &gt; = 4.0 ( +/ 0.5 ) x 10^7/kg If two CB unit use , total cell dose combine unit must least 3.0 x 10^7 TNC per kilogram recipient weight base precryopreservation number , CB unit contain MINIMUM 1.5 x 10^7 TNC/kg The minimum recommend CD34/kg cell dose 2 x 10^5 CD34/kg , total dose single combine double The unmanipulated CB unit ( ) Food Drug Administration ( FDA ) license obtain separate investigational new drug ( IND ) , National Marrow Donor Program ( NMDP ) Protocol 10CBA conduct BB IND7555 another IND sponsor ( 1 ) participate institution ( 2 ) investigator FHCRC one participate institution FHCRC : Up 5 % cord blood product , ready infusion , may withhold research purpose long threshold infuse TNC dose meet ; threshold double unit transplantation &gt; = 3.0 x 10^7/kg ; product use conduct study involve immunobiology double cord transplantation kinetics engraftment Patients available 56/6 HLAA , B , DRB1 match sibling donor Pregnancy breastfeed Evidence human immunodeficiency virus ( HIV ) infection know HIV positive serology Uncontrolled viral bacterial infection time study enrollment Active recent ( prior 6 month ) invasive fungal infection without infectious disease ( ID ) consult approval Active central nervous system malignancy DONOR : Any cord blood unit &lt; 1.5 x 10^7 total nucleated cell per kilogram recipient weight DONOR : Any cord blood unit without full maternal test negative result hepatitis A , B , C , HIV , human Tlymphotropic virus ( HTLV1 ) virus</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>